Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Other Non-Current Assets (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Other Non-Current Assets data on record, last reported at $1.1 million in Q1 2026.

  • On a quarterly basis, Other Non-Current Assets rose 400.95% to $1.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.1 million, a 400.95% increase, with the full-year FY2025 number at $985000.0, up 515.62% from a year prior.
  • Other Non-Current Assets reached $1.1 million in Q1 2026 per RAPP's latest filing, up from $985000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for RAPP hit a ceiling of $1.1 million in Q3 2025 and a floor of $160000.0 in Q4 2024.
  • A 4-year average of $604888.9 and a median of $551000.0 in 2023 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: crashed 70.96% in 2024, then soared 515.62% in 2025.
  • Tracing RAPP's Other Non-Current Assets over 4 years: stood at $551000.0 in 2023, then plummeted by 70.96% to $160000.0 in 2024, then skyrocketed by 515.62% to $985000.0 in 2025, then grew by 7.31% to $1.1 million in 2026.
  • Business Quant data shows Other Non-Current Assets for RAPP at $1.1 million in Q1 2026, $985000.0 in Q4 2025, and $1.1 million in Q3 2025.